IMM.L (MKap $85 M) Multiple Blockbuster Kandidat kurz vor final P3 Daten (1Q 2018) (Seite 103)
eröffnet am 10.05.17 14:44:50 von
neuester Beitrag 02.04.24 14:20:49 von
neuester Beitrag 02.04.24 14:20:49 von
Beiträge: 1.656
ID: 1.252.583
ID: 1.252.583
Aufrufe heute: 0
Gesamt: 222.554
Gesamt: 222.554
Aktive User: 0
ISIN: GB0033711010 · WKN: A0BMC4 · Symbol: IMM
0,0195
EUR
-6,70 %
-0,0014 EUR
Letzter Kurs 31.10.23 TTMzero
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 10,000 | +25,00 | |
| 6,0000 | +25,00 | |
| 0,7113 | +21,90 | |
| 0,6400 | +18,52 | |
| 1,0360 | +14,98 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,6000 | -12,16 | |
| 9,7200 | -19,60 | |
| 4,0000 | -27,27 | |
| 2,7280 | -29,14 | |
| 14,510 | -32,32 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 57.569.718 von Pat83 am 18.04.18 08:32:02Guten Morgen . Wie du ja selber schon gemerkt hast sieht jeder die Situation etwas anderst . Ich persönlich denke man muss jetzt einfach abwarten was da jetzt von der Firma kommt . Noch weiter zusammenbrechen denke / hoffe ich nicht . Die Firma besteht ja nicht nur aus Lupuzor das wird bei einer Übernahme hoffentlich auch berücksichtigt . Ich weis das ist nicht sonderlich hilfreich , aber eine eindeutige Einschätzung zum aktuellen Stand kann von uns hier sowieso wohl niemand geben . LG
Antwort auf Beitrag Nr.: 57.569.793 von lamaro am 18.04.18 08:37:05und was sagt uns das? Die P3 ist gescheitert daher ist das im Prinzip wertlos
Vielleicht haben sie
die FDA nicht genug geschmiert 62%
Das CNRS-Forscherteam hat nun eine Peptid-Familie (Proteinfragmente) entwickelt, die spezifisch die Fehlfunktionen des Immunsystems korrigieren. Das P1405 kann das Fortschreiten dieser Krankheit bei Mäusen hinauszuzögern, ohne das eigene Immunsystem zur Bekämpfung dieses Krankheitserregers zu aktivieren. In der Phase-II-Studie ging die Krankheit nach dreimonatiger Behandlung bei 62 Prozent der Patienten zurück. Dies ist das beste Ergebnis, das je bei der Behandlung von Lupus erzielt wurde.
Guten Morgen
Kann mal jemand die Zahlen erklären. Ich habe so ziemlich jeden Artikel gelesen und selten war ich so verwirrt. Die einen schreiben das das Medikament keine Wirkung hat und somit nicht zugelassen wird und andere schreiben das es besser ist wie der aktuelle Standart und keine Nebenwirkungen hat und somit wohl eine Zulassung bekommt.
Bei einigen steht das die Firma wohl verkauft wird zu einem Bruchteil des Wertes und der Aktienkurs nochmal zusammen bricht.. Andere schreiben das es wohl nochmal hochgeht und eine Übernahme bei ca 150 GBX erfolgt.. Ich kann das absolut nicht einschätzen.. Kann mir da jemand ein paar Tips geben?
Kann mal jemand die Zahlen erklären. Ich habe so ziemlich jeden Artikel gelesen und selten war ich so verwirrt. Die einen schreiben das das Medikament keine Wirkung hat und somit nicht zugelassen wird und andere schreiben das es besser ist wie der aktuelle Standart und keine Nebenwirkungen hat und somit wohl eine Zulassung bekommt.
Bei einigen steht das die Firma wohl verkauft wird zu einem Bruchteil des Wertes und der Aktienkurs nochmal zusammen bricht.. Andere schreiben das es wohl nochmal hochgeht und eine Übernahme bei ca 150 GBX erfolgt.. Ich kann das absolut nicht einschätzen.. Kann mir da jemand ein paar Tips geben?
Trading Spotlight
Ich denke mal, hier besteht noch berechtigte Hoffnung.
http://www.proactiveinvestors.co.uk/companies/news/195121/im…
ImmuPharma sees "significant opportunity" for lupus drug after phase III trial readout
15:13 17 Apr 2018
The company revealed there had been "expressions of interest" in its lupus programme which it will explore
researcher filling a vial
The effectiveness among the 153 patients that got to the end of the course of treatment was 68.8%
ImmuPharma PLC (LON:IMM) said it believes there is a “significant opportunity” for its drug Lupuzor, used to treat autoimmune disease lupus, following the release of top-line results from a phase III trial.
The data revealed Lupuzor was more effective than the placebo (52.5% versus 44.6%). But because the response rate for those taking the non-active medication plus the “standard of care” was so high the end-point of the study was not achieved. That 'end-point' was a statistically significant beneficial impact from Lupuzor.
This initial readout was based on 202 patients, including those who withdrew from the trial.
WATCH: Drug needs further analysis, City analyst
The effectiveness among the 153 that got to the end of the course of treatment was 68.8% (versus 59.2% for the placebo).
Importantly, in patients who had a certain type of lupus biomarker called anti-dsDNA autoantibodies, Lupuzor worked well when compared with the placebo. Added to that, 7.6% of this group went into full remission, while none did in the placebo group.
The safety profile remained good with no adverse effects
Chairman Tim McCarthy said: “Lupuzor has demonstrated, in this study, a superior response rate over placebo and its exceptional safety, giving it, we believe, a compelling product profile.
“Whilst we are disappointed at the high response in the placebo plus standard of care group that resulted in statistical significance not being reached between the two treatment groups, we believe Lupuzor has the potential to bring a much needed safe treatment to the millions of Lupus sufferers around the world.
“We look forward to providing our shareholders with further updates in due course."
Further investigation merited
ImmuPharma said it believes the top line results “provide evidence for the continued investigation into the development and commercialisation of Lupuzor”. It thinks the drug has the potential to offer patients and physicians a much needed effective and safe treatment for lupus.
Following requests from both investigators and patients, ImmuPharma has begun a further study. This will allow all patients who took part in the phase III trial to receive Lupuzor plus the ‘standard of care’ medication for six months in what’s called an open-label scheme.
The results will be gathered independent of the pivotal trial just completed.
The plan is to look at the full dataset before making a decision, but the company said there is demand for a new lupus treatment.
Expressions of interest
It also said there had been “expressions of interest” in the Lupuzor programme and the phase III study.
“ImmuPharma is in ongoing discussions with a number of larger pharmaceutical companies,” it added.
“The results of this study will now be shared with those potential commercial partners. There can be no certainty as to the outcome or timing of these discussions.”
http://www.proactiveinvestors.co.uk/companies/news/195121/im…
ImmuPharma sees "significant opportunity" for lupus drug after phase III trial readout
15:13 17 Apr 2018
The company revealed there had been "expressions of interest" in its lupus programme which it will explore
researcher filling a vial
The effectiveness among the 153 patients that got to the end of the course of treatment was 68.8%
ImmuPharma PLC (LON:IMM) said it believes there is a “significant opportunity” for its drug Lupuzor, used to treat autoimmune disease lupus, following the release of top-line results from a phase III trial.
The data revealed Lupuzor was more effective than the placebo (52.5% versus 44.6%). But because the response rate for those taking the non-active medication plus the “standard of care” was so high the end-point of the study was not achieved. That 'end-point' was a statistically significant beneficial impact from Lupuzor.
This initial readout was based on 202 patients, including those who withdrew from the trial.
WATCH: Drug needs further analysis, City analyst
The effectiveness among the 153 that got to the end of the course of treatment was 68.8% (versus 59.2% for the placebo).
Importantly, in patients who had a certain type of lupus biomarker called anti-dsDNA autoantibodies, Lupuzor worked well when compared with the placebo. Added to that, 7.6% of this group went into full remission, while none did in the placebo group.
The safety profile remained good with no adverse effects
Chairman Tim McCarthy said: “Lupuzor has demonstrated, in this study, a superior response rate over placebo and its exceptional safety, giving it, we believe, a compelling product profile.
“Whilst we are disappointed at the high response in the placebo plus standard of care group that resulted in statistical significance not being reached between the two treatment groups, we believe Lupuzor has the potential to bring a much needed safe treatment to the millions of Lupus sufferers around the world.
“We look forward to providing our shareholders with further updates in due course."
Further investigation merited
ImmuPharma said it believes the top line results “provide evidence for the continued investigation into the development and commercialisation of Lupuzor”. It thinks the drug has the potential to offer patients and physicians a much needed effective and safe treatment for lupus.
Following requests from both investigators and patients, ImmuPharma has begun a further study. This will allow all patients who took part in the phase III trial to receive Lupuzor plus the ‘standard of care’ medication for six months in what’s called an open-label scheme.
The results will be gathered independent of the pivotal trial just completed.
The plan is to look at the full dataset before making a decision, but the company said there is demand for a new lupus treatment.
Expressions of interest
It also said there had been “expressions of interest” in the Lupuzor programme and the phase III study.
“ImmuPharma is in ongoing discussions with a number of larger pharmaceutical companies,” it added.
“The results of this study will now be shared with those potential commercial partners. There can be no certainty as to the outcome or timing of these discussions.”
Antwort auf Beitrag Nr.: 57.564.135 von hamitc am 17.04.18 15:03:01Du hast verdoppelt und glaubst nicht an ein gutes Ende?
Antwort auf Beitrag Nr.: 57.563.280 von Twohybrid am 17.04.18 13:48:04@Twohybird: Hammer Beitrag!
Ich habe auch verdoppelt. Glaube nich an an gutes Ende! Die nächsten Tage werden Mega spannend!
Gruß.
Ich habe auch verdoppelt. Glaube nich an an gutes Ende! Die nächsten Tage werden Mega spannend!
Gruß.
Antwort auf Beitrag Nr.: 57.563.886 von Diversifikation am 17.04.18 14:45:23Gut. Dann hört sich immerhin untenstehendes positiv an.
•Importantly, in patients who had anti-dsDNA autoantibodies (a recognised biomarker for Systemic Lupus Erythematosus (‘SLE’)), Lupuzor™ demonstrated a superior response rate over placebo (61.5% vs 47.3%, p = 0.0967). In addition, 7.6% of these patients in the Lupuzor™ group went into full remission versus none in the placebo group.
•Importantly, in patients who had anti-dsDNA autoantibodies (a recognised biomarker for Systemic Lupus Erythematosus (‘SLE’)), Lupuzor™ demonstrated a superior response rate over placebo (61.5% vs 47.3%, p = 0.0967). In addition, 7.6% of these patients in the Lupuzor™ group went into full remission versus none in the placebo group.
Durchsuchen
